References
- Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350–1355. doi:https://doi.org/10.1126/science.aar4060.
- Gong J, Chehrazi-Raffle A, Reddi S, Salgia R. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J Immunother Cancer. 2018;6(1):8. doi:https://doi.org/10.1186/s40425-018-0316-z.
- Hodi FS, Chesney J, Pavlick AC, Robert C, Grossmann KF, McDermott DF, et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol. 2016;17(11):1558–1568. doi:https://doi.org/10.1016/S1470-2045(16)30366-7.
- Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34. doi:https://doi.org/10.1056/NEJMoa1504030.
- Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372(21):2006–2017. doi:https://doi.org/10.1056/NEJMoa1414428.
- Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob J-J, Cowey CL, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017;377(14):1345–1356. doi:https://doi.org/10.1056/NEJMoa1709684.
- Nishijima TF, Shachar SS, Nyrop KA, Muss HB. Safety and tolerability of PD-1/PD-L1 inhibitors compared with chemotherapy in patients with advanced cancer: a meta-analysis. Oncologist. 2017;22(4):470–479. doi:https://doi.org/10.1634/theoncologist.2016-0419.
- Wang DY, Salem J-E, Cohen JV, Chandra S, Menzer C, Ye F, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018;4(12):1721–1728. doi:https://doi.org/10.1001/jamaoncol.2018.3923.
- Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv119–iv142. doi:https://doi.org/10.1093/annonc/mdx225.
- Puzanov I, Diab A, Abdallah K, Bingham CO, Brogdon C, Dadu R, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer. 2017;5(1):95. doi:https://doi.org/10.1186/s40425-017-0300-z.
- Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36(17):1714–1768. doi:https://doi.org/10.1200/JCO.2017.77.6385.
- Thompson JA. New NCCN guidelines: recognition and management of immunotherapy-related toxicity. J Natl Compr Canc Netw. 2018;16(5S):594–596. doi:https://doi.org/10.6004/jnccn.2018.0047.
- Scher KS, Hurria A. Under-representation of older adults in cancer registration trials: known problem, little progress. J Clin Oncol. 2012;30(17):2036–2038. doi:https://doi.org/10.1200/JCO.2012.41.6727.
- Hurria A, Levit LA, Dale W, Mohile SG, Muss HB, Fehrenbacher L, et al. Improving the evidence base for treating older adults with cancer: American Society of Clinical Oncology statement. J Clin Oncol. 2015;33(32):3826–3833. doi:https://doi.org/10.1200/JCO.2015.63.0319.
- Levit LA, Singh H, Klepin HD, Hurria A. Expanding the evidence base in geriatric oncology: action items from an FDA-ASCO workshop. J Natl Cancer Inst. 2018;110(11):1163–1170. doi:https://doi.org/10.1093/jnci/djy169.
- Singh H, Hurria A, Klepin HD. Progress through collaboration: an ASCO and U.S. Food and Drug Administration workshop to improve the evidence base for treating older adults with cancer. Am Soc Clin Oncol Educ Book. 2018;(38):392–399. doi:https://doi.org/10.1200/EDBK_201133.
- Kanesvaran R, Cordoba R, Maggiore R. Immunotherapy in older adults with advanced cancers: implications for clinical decision-making and future research. Am Soc Clin Oncol Educ Book. 2018;(38):400–414. doi:https://doi.org/10.1200/EDBK_201435.
- Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613–619. doi:https://doi.org/10.1016/0895-4356(92)90133-8.
- Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000;53(12):1258–1267. doi:https://doi.org/10.1016/S0895-4356(00)00256-0.
- Bjørnhart B, Hansen KH, Jørgensen TL, Herrstedt J, Schytte T. Efficacy and safety of immune checkpoint inhibitors in a Danish real life non-small cell lung cancer population: a retrospective cohort study. Acta Oncologica. 2019;58(7):953–961. doi:https://doi.org/10.1080/0284186X.2019.1615636.
- Austin SR, Wong YN, Uzzo RG, Beck JR, Egleston BL. Why summary comorbidity measures such as the Charlson Comorbidity Index and Elixhauser Score Work. Med Care. 2015;53(9):e65–e72. doi:https://doi.org/10.1097/MLR.0b013e318297429c.
- Sales AE, Liu C-F, Sloan KL, Malkin J, Fishman PA, Rosen AK, et al. Predicting costs of care using a pharmacy-based measure risk adjustment in a veteran population. Med Care. 2003;41(6):753–760. doi:https://doi.org/10.1097/01.MLR.0000069502.75914.DD.
- Sloan KL, Sales AE, Liu C-F, Fishman P, Nichol P, Suzuki NT, et al. Construction and characteristics of the RxRisk-V: a VA-adapted pharmacy-based case-mix instrument. Med Care. 2003;41(6):761–774. doi:https://doi.org/10.1097/01.MLR.0000064641.84967.B7.
- Fan VS, Maciejewski ML, Liu C-F, McDonell MB, Fihn SD. Comparison of risk adjustment measures based on self-report, administrative data, and pharmacy records to predict clinical outcomes. Health Serv Outcomes Res Method. 2006;6(1–2):21–36. doi:https://doi.org/10.1007/s10742-006-0004-1.
- Hart LG, Larson EH, Lishner DM. Rural definitions for health policy and research. Am J Public Health. 2005;95(7):1149–1155. doi:https://doi.org/10.2105/AJPH.2004.042432.
- West AN, Weeks WB, Wallace AE. Rural veterans and access to high-quality care for high-risk surgeries. Health Serv Res. 2008;43(5 Pt 1):1737–1751. doi:https://doi.org/10.1111/j.1475-6773.2008.00876.x.
- Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369(2):122–133. doi:https://doi.org/10.1056/NEJMoa1302369.
- Kehl KL, Yang S, Awad MM, Palmer N, Kohane IS, Schrag D. Pre-existing autoimmune disease and the risk of immune-related adverse events among patients receiving checkpoint inhibitors for cancer. Cancer Immunol Immunother. 2019;68(6):917–926. doi:https://doi.org/10.1007/s00262-019-02321-z.